Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, has closed a $100 million Series B financing led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. “This financing is a testament to the science, strategy, and team we have built at Neomorph, and it provides us with the capital to ...